Novo Holdings A/S’s BioMarin Pharmaceuticals BMRN Stock Holding History

Novo Holdings A/S’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-660,000	Closed	-$37.3M	–	27
2026 Q1	$37.3M	Hold	660,000	–	–	3.02%	15
2025 Q4	$39.2M	Hold	660,000	–	–	3.05%	13
2025 Q3	$35.7M	Hold	660,000	–	–	2.3%	15
2025 Q2	$36.3M	Buy	660,000 +170,000	+35%	+$10M	2.56%	13
2025 Q1	$34.6M	Hold	490,000	–	–	2.63%	11
2024 Q4	$32.2M	Hold	490,000	–	–	1.95%	16
2024 Q3	$34.4M	Hold	490,000	–	–	1.71%	17
2024 Q2	$40.3M	Buy	490,000 +40,000	+9%	+$3.33M	2.17%	13
2024 Q1	$39.3M	Hold	450,000	–	–	2.71%	11
2023 Q4	$43.4M	Buy	450,000 +50,000	+13%	+$4.42M	2.68%	12
2023 Q3	$35.4M	Hold	400,000	–	–	2.62%	14
2023 Q2	$34.7M	Buy	400,000 +32,620	+9%	+$3.07M	2.68%	13
2023 Q1	$35.7M	Buy	367,380 +49,680	+16%	+$5.15M	2.36%	16
2022 Q4	$32.9M	Buy	317,700 +200	+0.1%	+$18.8K	2.05%	17
2022 Q3	$26.9M	Hold	317,500	–	–	1.28%	18
2022 Q2	$26.3M	Buy	+317,500	New	+$25.3M	1.3%	19

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Novo Holdings A/S's BMRN Position: Q2 2026 in Review

Novo Holdings A/S sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 660,000 shares — an estimated $37.3M sold.

Novo Holdings A/S first reported a position in BMRN in Q2 2022 and held it in 16 quarters. The position peaked at $43.4M in Q4 2023. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Novo Holdings A/S reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Novo Holdings A/S sold 660,000 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $37.3M.
Novo Holdings A/S first reported a position in BioMarin Pharmaceuticals in Q2 2022 and held it in 16 quarters.
Novo Holdings A/S's BioMarin Pharmaceuticals position peaked at $43.4M in Q4 2023.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Novo Holdings A/S's 13F filing for Q2 2026, filed 14 Aug 2026.